相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。PARP inhibitors in ovarian cancer
Elisena Franzese et al.
CANCER TREATMENT REVIEWS (2019)
Exploring and comparing adverse events between PARP inhibitors
Christopher J. LaFargue et al.
LANCET ONCOLOGY (2019)
Inhibition of autophagy potentiated the anti-tumor effects of VEGF and CD47 bispecific therapy in glioblastoma
Xuyao Zhang et al.
APPLIED MICROBIOLOGY AND BIOTECHNOLOGY (2018)
Disrupting CD47-SIRP alpha axis alone or combined with autophagy depletion for the therapy of glioblastoma
Xuyao Zhang et al.
CARCINOGENESIS (2018)
Update on PARP Inhibitors in Breast Cancer
Alexandra S. Zimmer et al.
CURRENT TREATMENT OPTIONS IN ONCOLOGY (2018)
Allelic Polymorphisms of KIRs and HLAs Predict Favorable Responses to Tyrosine Kinase Inhibitors in CML
Hiroshi Ureshino et al.
CANCER IMMUNOLOGY RESEARCH (2018)
Targeting Tissue Factor for Immunotherapy of Triple-Negative Breast Cancer Using a Second-Generation ICON
Zhiwei Hu et al.
CANCER IMMUNOLOGY RESEARCH (2018)
Secretory IgM Exacerbates Tumor Progression by Inducing Accumulations of MDSCs in Mice
Chih-Hang Anthony Tang et al.
CANCER IMMUNOLOGY RESEARCH (2018)
CCL20 Expression by Tumor-Associated Macrophages Predicts Progression of Human Primary Cutaneous Melanoma
Rafael Samaniego et al.
CANCER IMMUNOLOGY RESEARCH (2018)
Exosomes Associated with Human Ovarian Tumors Harbor a Reversible Checkpoint of T-cell Responses
Gautam N. Shenoy et al.
CANCER IMMUNOLOGY RESEARCH (2018)
Programmed Cell Death Ligand 1 (PD-L1) Signaling Regulates Macrophage Proliferation and Activation
Genevieve P. Hartley et al.
CANCER IMMUNOLOGY RESEARCH (2018)
Activity of durvalumab plus olaparib in metastatic castration-resistant prostate cancer in men with and without DNA damage repair mutations
Fatima Karzai et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2018)
Tumor cell-released autophagosomes (TRAPs) promote immunosuppression through induction of M2-like macrophages with increased expression of PD-L1
Zhi-Fa Wen et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2018)
Immunotherapy utilizing the combination of natural killer- and antibody dependent cellular cytotoxicity (ADCC)-mediating agents with poly (ADP-ribose) polymerase (PARP) inhibition
Kathleen E. Fenerty et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2018)
Rational combination therapy with PARP and MEK inhibitors capitalizes on therapeutic liabilities in RAS mutant cancers
Chaoyang Sun et al.
SCIENCE TRANSLATIONAL MEDICINE (2017)
A novel and promising therapeutic approach for NSCLC: recombinant human arginase alone or combined with autophagy inhibitor
Weitao Shen et al.
CELL DEATH & DISEASE (2017)
Autophagy suppression potentiates the anti-glioblastoma effect of asparaginase in vitro and in vivo
Qicheng Chen et al.
ONCOTARGET (2017)
Targeting CD47 and Autophagy Elicited Enhanced Antitumor Effects in Non-Small Cell Lung Cancer
Xuyao Zhang et al.
CANCER IMMUNOLOGY RESEARCH (2017)
Poly (ADP-Ribose) Polymerase Inhibitors: Recent Advances and Future Development
Clare L. Scott et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Loss of autophagy causes a synthetic lethal deficiency in DNA repair
Emma Y. Liu et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2015)
ARHI (DIRAS3)-mediated autophagy-associated cell death enhances chemosensitivity to cisplatin in ovarian cancer cell lines and xenografts
M. N. Washington et al.
CELL DEATH & DISEASE (2015)
Compromised CDK1 activity sensitizes BRCA-proficient cancers to PARP inhibition
Neil Johnson et al.
NATURE MEDICINE (2011)
PARP inhibition: PARP1 and beyond
Michele Rouleau et al.
NATURE REVIEWS CANCER (2010)
Regulation Mechanisms and Signaling Pathways of Autophagy
Congcong He et al.
ANNUAL REVIEW OF GENETICS (2009)
A synthetic lethal therapeutic approach: Poly(ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair
Alan Ashworth
JOURNAL OF CLINICAL ONCOLOGY (2008)
Autophagy mitigates metabolic stress and genome damage in mammary tumorigenesis
Vassiliki Karantza-Wadsworth et al.
GENES & DEVELOPMENT (2007)
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy
H Farmer et al.
NATURE (2005)
分享论文
